Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946088 | 1.00 | SLC6A4 (0.53) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL635989 | 0.86 | SLC6A4 (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL637388 | 0.80 | SLC6A4 (0.50) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL6325819 | 0.76 | SLC6A4 (0.54) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL6327948 | 0.76 | SLC6A4 (0.57) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 | |
| SCHEMBL636098 | 0.74 | SLC6A4 (0.51) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL2837925 | 0.74 | SLC6A4 (0.46) | SLC6A4CYP1A2CYP2D6CYP2C19MAOA | |
| SCHEMBL636461 | 0.74 | SLC6A4 (0.46) | SLC6A4CYP1A2CYP2D6CYP2C19MAOA | |
| SCHEMBL162234 | 0.74 | SLC6A4 (0.46) | SLC6A4CYP1A2CYP2D6CYP2C19MAOA | |
| SCHEMBL2362537 | 0.74 | SLC6A4 (0.50) | SLC6A4CYP1A2CYP2D6CYP2C19IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | claimed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | claimed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | claimed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | claimed |
| EP-1411045-B1 | Process for production of optically active amino alcohols | YOKOZAWA TOHRU (JP) | 2008-01-16 | — | — | EP | claimed |
| US-6984738-B2 | Process for production of optically active amino alcohols | YOKOZAWA TOHRU | 2006-01-10 | — | — | US | claimed |
| EP-4610268-A1 | CELL-MEMBRANE-PERMEABLE PEPTIDE FOR CONJUGATION | AGC INC. (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024090491-A1 | CELL-MEMBRANE-PERMEABLE PEPTIDE FOR CONJUGATION | ＡＧＣ株式会社 | 2024-05-02 | — | — | WO | disclosed |
| WO-2022149584-A1 | PEPTIDE | ＡＧＣ株式会社 | 2022-07-14 | — | — | WO | disclosed |
| EP-3995486-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC INC. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-6787676-B2 | REACTING A CARBONYL COMPOUND WITH HYDROGEN IN THE PRESENCE OF A CATALYST, A BASE AND OPTIONALLY A DIAMINE, WHERE THE CATALYST IS A SUPPORT-BONDED RUTHENIUM(II) COMPLEX BISPHOSPHINE LIGAND AND A DIAMINE LIGAND | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2004-09-07 | — | — | US | disclosed |
| US-20040082794-A1 | Process for production of optically active amino alcohols | YOKOZAWA TOHRU (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1411045-A1 | Process for production of optically active amino alcohols | Yokozawa, Tohru (JP) | 2004-04-21 | — | — | EP | disclosed |
| EP-1299401-B1 | CHIRAL LIGANDS FOR ASYMMETRIC CATALYSIS | CHIROTECH TECHNOLOGY LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-6508753-B2 | Hydrogenation catalyst | CHIROTECH TECHNOLOGY LIMITED (GB) | 2003-01-21 | — | — | US | disclosed |
| US-20020111515-A1 | Reacting a carbonyl compound with hydrogen in the presence of a catalyst, a base and optionally a diamine, where the catalyst is a support-bonded ruthenium(II) complex bisphosphine ligand and a diamine ligand | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2002-08-15 | — | — | US | disclosed |
| US-20020035285-A1 | Chiral ligands for asymmetric catalysis | CHIROTECH TECHNOLOGY LIMITED (GB) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111515-A1 | Reacting a carbonyl compound with hydrogen in the presence of a catalyst, a base and optionally a diamine, where the catalyst is a support-bonded ruthenium(II) complex bisphosphine ligand and a diamine ligand | PDK1, ADH1A, HRH3 | SLC6A4 4046/4885CYP1A2 2624/4885CYP2D6 2665/4885 |
| US-20020035285-A1 | Chiral ligands for asymmetric catalysis | AR, NR5A2, NR5A1 | SLC6A4 3517/4885CYP1A2 860/4885CYP2D6 2071/4885 |
| US-20040082794-A1 | Process for production of optically active amino alcohols | ADH5, ADH1C, ADH1A | SLC6A4 1274/4885CYP1A2 93/4885CYP2D6 388/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SLC6A4 1615/4885CYP1A2 1113/4885CYP2D6 484/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | SLC6A4 3807/4885CYP1A2 45/4885CYP2D6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.